Diego Miralles, M.D.

President and Head of Research and Development

Dr. Miralles brings more than 20 years of global leadership experience spanning research, clinical development, commercialization and company building across biotechnology and large pharmaceutical companies. He served as chief executive officer of Laronde Inc., a Flagship Pioneering company developing a programmable RNA platform to produce therapeutic proteins. Prior to Laronde, Dr. Miralles served as chief executive officer of Vividion Therapeutics, where he built the company from inception into a leading chemical biology platform for the discovery of small molecule therapies against previously undruggable targets. Prior to Vividion, Dr. Miralles served as president of Adaptive Therapeutics, a division of Adaptive Biotechnologies, and as global head of Johnson & Johnson Innovation, where he founded the Johnson & Johnson Innovation Centers and JLABS. Earlier in his career at Johnson & Johnson, he led the Janssen Research and Early Development unit in La Jolla, California and served as vice president of clinical development at Tibotec, where he was involved in the development, approval and commercialization of several antiviral medicines, including PREZISTA® and INTELENCE®. Dr. Miralles has served on Artiva’s Board of Directors since May 2024 and currently serves on the boards of directors of Contineum Therapeutics, ArrePath Therapeutics and Rady Children’s Hospital of San Diego. Dr. Miralles received his M.D. from the Universidad de Buenos Aires, Argentina, completed his internal medicine residency at the Mayo Clinic and was a fellow in infectious diseases at Cornell University–New York Hospital.